Nephroprotection and vascular risk: Prevention of renal damage in hypertension;Nefroprotección y riesgo vascular: Prevención del daño renal en la hipertensión arterial

Revista Clinica Espanola

Volumn 211, Issue SUPPL. 1, 2011, Pages 15-20

  Galceran Gui J M ^a  

^a UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Diabetes; Hypertension; Hypertensive nephropathy; Proteinuria; Renal insufficiency; Renal protection; Renin angiotensin system

Indexed keywords

ARTICLE; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; KIDNEY INJURY; KIDNEY PRESERVATION; RENAL PROTECTION;

HUMANS; HYPERTENSION; KIDNEY DISEASES;

EID: 79953687685     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(11)70004-2     Document Type: Article

References (30)

1. G.A. Perera Hypertensive vascular disease: description and natural history J Chronic Dis 1 1995 33 42
2. S. Gracia, R. Montañés, J. Bover, A. Cases, R. Deulofeu, and A.L. Martín de Francisco Recomendaciones sobre la utilización de ecuaciones para la estimación del filtrado glomerular en adultos Nefrología 26 2006 658 665
3. A. Otero, A. De Francisco, P. Gayoso, F. García On behalf of the EPIRCE Study Group Prevalence of chronic renal disease in Spain: Results of the EPIRCE study Nefrología 30 2010 78 86
4. P. Herrero, R. Marín, F. Fernández Vega, M. Gorostidi, A. Riesgo, and J. Vázquez Renal function and cardiovascular risk in patients with essential hypertension. The "FRESHA" study Nefrología 26 2006 330 338 (Pubitemid 44898040)
5. Centers for Disease Control and Prevention (CDC) State-specific trends in chronic kidney failure - United States, 1990-2001 MMWR Morb Mortal Wkly Rep 53 2004 918 920
6. M. Nagata, T. Ninomiya, Y. Doi, K. Yonemoto, M. Kubo, and J. Hata Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama Study Nephrol Dial Transplant 25 2010 2557 2564
7. J. Wright, and A. Hutchison Cardiovascular disease in patients with chronic kidney disease Vasc Health Risk Manag 5 2009 713 722
8. S.I. Hallan, K. Dahl, C.M. Oien, D.C. Grootendorst, A. Aasberg, and J. Holmen Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey BMJ 333 2006 1047 1054
9. J.M. Galcerán Riesgo por enfermedad renal crónica: la epidemia revisada Hipertens Riesgo Vasc 27 2010 183 186
10. A.K. Bidani, and K.A. Griffin Pathophysiology of Hypertensive Renal Damage Hipertensión 44 2004 595 601
11. A. Levin, B. Hemmelgarn, B. Culleton, S. Tobe, P. McFarlane, and M. Ruzicka Guidelines for the management of chronic kidney disease CMAJ 179 2008 1154 1162
12. D. Harris, M. Thomas, D. Johnson, K. Nicholls, A. Gillin Caring for Australasians with Renal Impairment (CARI). The CARI guidelines Prevention of progression of kidney disease Nephrology (Carlton) 11 Suppl 1 2006 S2 S197
13. Chronic Kidney Disease. Medicare Quality Improvement Project. Disponible en: http:/www.fmqai.com
14. I.M. Van der Meer, P. Cravedi, and G. Remuzzi The role of renin angiotensin system inhibition in kidney repair Fibrogenesis Tissue Repair 3 2010 7
15. E.A. Jaimes, J.M. Galceran, and L. Raij Angiotensin II induces superoxide anion production by mesangial cells Kidney Int 54 1998 775 784 (Pubitemid 28397395)
16. G.L. Bakris Maximizing cardiorenal benefit in the management of hypertension: achieve blood pressure goals J Clin Hypertens 1 1999 141 147
17. T.H. Jafar, P.C. Stark, C.H. Schmid, M. Landa, G. Maschio, and C. Marcantoni Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease Kidney Int 60 2001 1131 1140 (Pubitemid 34205814)
18. S.J. Chadban, E.M. Briganti, P.G. Kerr, D.W. Dunstan, T.A. Welborn, and P.Z. Zimmet Prevalence of kidney damage in Australian adults: The AusDiab kidney study J Am Soc Nephrol 14 2003 S131 S138
19. J.C. Peterson, S. Adler, J.M. Burkart, T. Greene, L.A. Hebert, and L.G. Hunsicker Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 1995 754 762
20. L.J. Appel, J.T. Wright Jr., T. Greene, L.Y. Agodoa, B.C. Astor, and G.L. Bakris Intensive blood-pressure control in hypertensive chronic kidney disease New Engl J Med 363 2010 918 929
21. S.M. Voyaki, J.A. Staessen, L. Thijs, J.G. Wang, A.D. Efstratopoulos, and W.H. Birkenhäger Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators J Hypertens 19 2001 511 519 (Pubitemid 32195388)
22. N.S. Beckett, R. Peters, A.E. Fletcher, J.A. Staessen, L. Liu, and D. Dumitrascu Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1887 1898 (Pubitemid 351620109)
23. J.F. Mann, R.E. Schmieder, M. McQueen, L. Dyal, H. Schumacher, and J. Pogue Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
24. M. Rahman, S. Pressel, B.R. Davis, C. Nwachuku, J.T. Wright Jr, and P.K. Whelton Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 165 2005 936 946 (Pubitemid 40563242)
25. M.J. Brown, C.R. Palmer, A. Castaigne, P.W. De Leeuw, G. Mancia, and T. Rosenthal Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356 2000 366 372 (Pubitemid 30487492)
26. J.M. Galcerán, G. Rehues, and M.J. Zamora Efecto multiplicador de glucosa y angiotensina II en la nefropatía diabética experimental Hipertensión 18 2001 (Num. ext.):54
27. P. Ruggenenti, A. Fassi, A.P. Ilieva, S. Bruno, I.P. Iliev, and V. Brusegan Preventing Microalbuminuria in Type 2 Diabetes N Engl J Med 351 2004 1941 1951 (Pubitemid 39447135)
28. H. Haller, S. Ito, and J.L. Izzo Prevention of microalbuminuria in type 2 diabetes (roadmap trial): 6A.02 J Hypertens 28 Suppl 2010 e233
29. K. Jamerson, M.A. Weber, G.L. Bakris, B. Dahlöf, B. Pitt, and V. Shi Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
30. G.L. Bakris, P.A. Sarafidis, M.R. Weir, B. Dahlöf, B. Pitt, and K. Jamerson Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial Lancet 375 2010 1173 1181